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Two hundred thirty-one patients with a first acute myocar. 
dial infarction were randomly allocated within 5 h after the 
onset of symptoms either to treatment with anisoylated 
plasminogen streptokinase activator complex (APSAC), 30 
U over 5 min, or to conventional heparin therapy, 5,000 IU 
in a bolus injection. Heparin was reintroduced in both 
groups 4 h after initial therapy at a dosage of 500 W/kg per 
day. One hundred twelve patients received APSAC and 119 
received heparin within a mean period of 188 + 62 min 
after the onset of symptoms. Both groups were similar in 
age, location of the acute myocardial infarction, Killip 
functional class and time of randomization. Elective core. 
nary arteriography was performed on an average of 4 f 1.2 
days after initial therapy. 
Follow-up radionuclide angiography and thallium-201 
single photon emission computed tomography were per- 
formed before hospital discharge. Infarct size was esti- 
mated from single photon emission computed tomography 
and expressed as a percent of total myocardial volume. The 
patency rate of the infarct-related artery was 77% in the 
APSAC group and 36% in the heparin group (p < 0.001). 
Left ventricular ejection fraction determined from contrast 
angiography was significantly higher in the APSAC group 
than in the heparin group. This was true for the entire 
study group (0.53 + 0.13 versus 0.47 + 0.12; p = 0.002) as 
well as for the subgroups of patients with anterior and 
inferior wall infarction (0.47 + 0.13 versus 0.40 -C 0.11; 
p = 0.04 and 0.56 + 0.10 versus 0.51 + 0.11; p = 0.02, 
respectively). At 3 weeks, the difference remained signifi- 
cant for the anterior myocardial infarction subgroup. A 
significant 31% reduction in infarct size was found in the 
APSAC group (33% for the anterior infarction subgroup 
[p < 0.051 and 16% for the inferior infarction subgroup 
[p = NS]). A close inverse relation was found between the 
values of left ventricular ejection fraction and infarct size 
(r = -0.73, p < 0.01). By the end of a 3 week follow-up 
period, seven APSAC-treated patients and six heparin- 
treated patients had died. 
In conclusion, the early infusion of APSAC in acute 
myocardial infarction produced a high early patency rate, 
significant limitation of infarct size and significant preser- 
vation of left ventricular systolic function, mainly in ante- 
rior wall infarction. 
(J Am Co11 Cardiol1989;13:988-97) 
Anisoylated plasminogen streptokinase activator complex 
(APSAC) is a complex of streptokinase and human lys- 
plasminogen synthesized to improve the kinetics of the 
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plasminogen-streptokinase complex. Its catalytic center is 
protected by an acyl group so that nonspecific activation of 
plasminogen and fibrinogenolysis can be avoided after injec- 
tion of the drug. Activation of APSAC bound to the fibrin of 
clot theoretically confers a fibrin specificity to the drug. In 
fact, when the drug is administered intravenously to patients 
in therapeutic doses (that is, 30 U), systemic fibrinogenolysis 
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is constant. Progressive deacylation after injection confers a 
prolonged half-life to the drug, averaging 90 min compared 
with 23 min with streptokinase, 16 min with urokinase and 5 
to 8 min with one and two chain recombinant plasminogen 
activator @t-PA). This prolonged half-life results in long- 
lasting thrombolytic effects. Because the intravenous injec- 
tion of the complex does not cause profound hemodynamic 
effects, the drug can be administered in a bolus injection 
(l-8). 
Previous trials of APSAC (9-16) have shown it to be well 
tolerated and well suited for emergency therapy of acute 
myocardial infarction. High reperfusion rates have been 
obtained with bolus intravenous injections of 30 U over 2 to 
5 min, with the time from injection to reperfusion averaging 
43 min. The reperfusion rate has been as high as 60% in 
patients treated for acute myocardial infarction within 4 h 
after the onset of symptoms (17). This reperfusion rate is as 
high as that obtained by administration of intracoronary 
streptokinase (17) and intravenous rt-PA (18). 
However, the results of prompt reperfusion obtained with 
APSAC on left ventricular performance and infarct size have 
seldom been studied. Therefore, the aim of this study was to 
compare the patency rate of the infarct-related artery. left 
ventricular function, infarct size and in-hospital mortality 
rate in patients with a recent acute myocardial infarction and 
randomly allocated either to treatment with APSAC or to 
conventional heparin therapy. 
Methods 
Design of the study. A multicenter randomized trial was 
conducted at 24 hospitals (3 university hospitals and 21 
affiliated community hospitals without catheterization facil- 
ities) in three provinces in France. Any patient 570 years old 
with a first acute transmural myocardial infarction referred 
to any of the hospitals involved in the trial within the first 5 
h after the onset of symptoms was eligible for randomiza- 
tion. The criterion for the initial diagnosis of evolving 
myocardial infarction was r2 mm ST segment elevation in at 
least two leads with or without Q waves, uninfluenced by 0.4 
mg of sublingual nitroglycerin. Exclusion criteria were I) 
chest pain lasting ~20 min or relieved by sublingual nitro- 
glycerin; 2) history of recent stroke. surgery or trauma; 3) 
predisposition to bleeding; 4) history of previous myocardial 
infarction with proved preexisting Q waves in at least two 
adjacent leads; 5) coronary artery bypass surgery: 6) cardio- 
genie shock defined as systolic blood pressure ~80 mm Hg 
unresponsive to rapid infusion of plasma or 0.5 mg atropine 
sulfate, or both, intravenously; 7) effective oral anticoagu- 
lant therapy at admission; 8) permanent severe systemic 
hypertension: 9) ongoing gastroduodenal ulcer: and 10) 
recent external cardiac massage. 
After providing informed consent, the patients were 
allocated either to intravenous conventional heparin therapy 
or to treatment with intravenous APSAC according to a 
double blind-double dummy procedure. In the first arm of 
the trial, called the heparin group, patients received a bolus 
injection of 5.000 IU of heparin and an APSAC placebo over 
5 min. Heparin was given in the first trial arm since, in 
France. this drug is considered mandatory in the conven- 
tional treatment of myocardial infarction. In the second trial 
arm, called the APSAC group, patients received 30 U of 
APSAC intravenously over 5 min and a heparin placebo. 
Heparin was reintroduced in both groups 4 h after initial 
therapy at a dosage of 500 N/kg per day and maintained for 
at least 7 days, after which acenocoumarol was introduced. 
Calcium channel and beta-adrenergic blockers were not 
allowed during the first 6 h of evolution. The decision to use 
any other medication or procedure as required by a patient’s 
condition was left to the initiative of the patient’s physician. 
Aspirin was not used in this protocol because its properties 
in acute myocardial infarction were not fully recognized at 
the time this study was designed. 
Electrocardiographic (ECG) recordings were made on 
admission at 6 and 24 h after initial therapy and at any time 
in the case of recurrence of chest pain. Standard laboratory 
tests including a complete blood count, serum creatine 
kinase MB isoenzyme. fibrinogen level and partially acti- 
vated thromboplastin time were made at admission and 6 and 
24 h after the initiation of therapy. Coagulation tests were 
repeated once or twice daily after the frst 24 h of evolution 
in order to adapt the anticoagulant therapy. 
Posttherapy procedures. After initial therapy, patients 
were referred to the university hospital of the corresponding 
province, where they were submitted to coronary angiogra- 
phy and left ventricuiogrdphy within 7 days after the onset of 
symptoms, and to radionuclide angiography and single pho- 
ton emission computed tomography within the 3rd week 
after the onset of symptoms. 
Coronary arteriography. This was performed by the fem- 
oral percutaneous approach. Multiple views of the right and 
left coronary systems were obtained in right and left anterior 
oblique projections, with at least two orthogonal views for 
each coronary system before and after intracoronary injec- 
tion of 3 mg of isosorbide dinitrate. Angulated craniocaudal 
views were used as well. Two independent experienced 
angiographers, working separately and without knowledge 
of patient data, analyzed all the coronary angiograms from 
each of the three centers. They were required to quantify the 
severity of stenosis of both the infarct-related artery and the 
noninvolved arteries for all angiograms. The severity of 
stenosis was subjectively estimated according to a five grade 
scoring system, in which 0 = occlusion, I = 95% luminal 
obstruction with delayed runoff of dye distal to the lesion, 
2 = 95% luminal obstruction without delayed runoff of dye, 
3 = 7.5% to 95% luminal obstruction. and 4 = ~75% luminal 
obstruction (nonsignificant lesion). The infarct-related artery 
was judged to be occluded if graded 0 or I and patent if 
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graded 2, 3 or 4. Differences in grading were resolved by 
consensus of the two observers and the principal investiga- 
tors. In cases of inferior infarction involving equivalent 
lesions of the right and left circumflex coronary arteries, the 
location of the left ventricular regional wall motion abnor- 
mality determined from the biplane left ventricular angio- 
gram was used to determine which artery was most likely to 
be responsible for the necrosis. 
Biplane left ventricular angiography. This was performed 
in each patient in a 30” right anterior oblique and a 60” left 
anterior oblique projection. The left ventricular volumes and 
ejection fraction were determined from the 30” right anterior 
oblique angiogram. Regional wall motion was analyzed 
according to the method of Leighton et al. (19). 
The long axis of the left ventricle was determined as the 
axis crossing the apex and dividing the left ventricular 
silhouette in two equal areas. The left ventricular end- 
systolic frame was superimposed onto the end-diastolic 
frame so as to realign both long axes. Ten anterior hemiaxes 
and 10 inferior hemiaxes were then drawn perpendicular to 
the end-diastolic long axis. The 20 hemiaxes were given a 
score according to the magnitude of the fractional shortening 
measured on each of them: 0 = fractional shortening within 
the normal range (estimated from the left ventricular angio- 
gram in 30 patients with chest pain and normal coronary 
arteries and considered to be normal); 1 = fractional short- 
ening ranging from -2 SD from normal and 20% shortening; 
2 = fractional shortening between 5% and 20%; and 3 = 
fractional shortening ~5% including negative values. A 
global semiquantitative asynergic score was obtained by 
adding the values from all 20 hemiaxes. All left ventricular 
angiograms from each of the three centers were blindly 
processed at a single center by two independent angiogra- 
phers. The average value of each determination was used for 
statistical analysis of results. 
Single photon emission computed tomography. For the 
isotopic studies, the cameras and computers used at each 
university center in this trial were of the same make and 
model. The acquisition of data was performed with use of the 
same labeling techniques and the same computer programs 
at all three centers. 
Myocardial scintigraphy was performed with 1.1 mBq (30 
&i)/kg dose of thallium-201 chloride injected with the 
patient at rest in the sitting position. Ten minutes later, a 
single photon emission computed tomographic acquisition 
was started, using a rotating large field scintillation camera 
equipped with a low energy, high resolution collimator. 
Spectrometry was set with a 25% window over the 69 to 83 
keV X-rays and with a 15% window over the 167 keV gamma 
rays of thallium-201. Thirty-two 30 s views were collected 
during a 180” rotation of the camera head between the left 
posterior and right anterior oblique projections. Each pro- 
jection was stored as a 64 x 64 matrix in a dedicated 
computer. All thallium-201 studies from each of the three 
Figure 1. Horizontal section of single photon emission computed 
tomographic image exemplifying the method of drawing the bound- 
aries of the infarct zone by interpolation between its endocardial and 
epicardial borders. 
centers were processed at one center, independently by two 
observers who did not know the treatment of the patients. 
Reconstruction of adjacent 1 pixel thick transverse sections 
was performed with use of a backprojection algorithm with a 
pure ramp filter. Sagittal sections were then obtained. Both 
series were smoothed with use of a three-dimensional filter. 
Defect size was measured on the most appropriate series 
(that is, the transverse sections for anterior and lateral 
infarcts, and the sagittal sections for inferior infarcts). The 
limits of the normal myocardium were delineated by the 
isocount activity line corresponding to 35% of the highest 
activity in the entire myocardium. The limits of the defect 
were drawn manually by interpolating between its endocar- 
dial and epicardial borders (Fig. 1). Normal muscle and 
defect volumes were calculated by summation of the number 
of pixels belonging to the normal myocardium and to the 
defect on all the sections passing through the myocardium. 
Infarct size was expressed as a percent of the entire myo- 
cardial volume. This method has allowed accurate determi- 
nation of infarct size in laboratory animals (20). 
Radionuclide angiography (ejection fraction). Immedi- 
ately after completion of the thallium-201 scintigraphic ac- 
quisition, each patient was injected with a 74 mBq (20 mCi) 
dose of technetium-99m human serum albumin. Sixteen 64 x 
64 frames were collected in the left anterior oblique projec- 
tion. All radionuclide studies from each of the three centers 
were processed at one center, other than the thallium-201 
processing center, by two independent observers working 
separately and unaware of the patients’ treatment. A routine 
semiautomatic method using two left ventricular regions of 
interest was used to calculate global left ventricular ejection 
fraction. Regional ejection fractions were estimated on 16 
sectors (Fig. 2) (21). Sectors 5 to 8 represented the septal 
region, sectors 9 to 11 the anteroapical region and sectors 12 
to 15 the lateral region of the left ventricle. Sectors 1 to 4 and 
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Figure 2. Drawing representing a left anterior oblique radionuclide 
angiographic view of the left ventricle, with the 11 angular sectors 
from which regional ejection fraction was estimated. Sectors 5 to 8 
represent the septal region, sectors 9 to 11 the apical region and 
sectors 12 to 15 the lateral region of the left ventricle. Sectors 1 to 4 
and 16 represent the mitral and aortic area and are not considered 
for the evaluation of regional wall motion. 
16 were not taken into account because they represent the 
mitral and aortic valve areas. In the laboratory in charge of 
processing the radionuclide angiograms, left ventricular 
ejection fraction estimated by this method is well correlated 
with left ventricular ejection fraction determined by contrast 
angiography, but with a constant underestimation due to the 
method of correcting background activity (y = 0.75 x +0.06, 
r = 0.94). 
Statistical analysis. Student’s t test, single linear regres- 
sion analysis and chi-square analysis were used to compare 
the two treatmem groups. All values were expressed as 
mean 4 SD. 
Results 
Study patients (Table 1). From June I, 1986 to July I, 
1987, 231 patients were recruited. A total of I I9 received 
Table 1. Description of the Overall Patient Study Group in 
the Trial 
Heparin APSAC p Value 
No. of patients 119 112 NS 
Male 107 I04 NS 
Age (mean 2 SD) (yr) 56 + 9 55 2 8 NS 
Anterior MI .5 I 45 NS 
Inferior Ml 6X 67 NS 
Time of randomization tmin) 189 i 64 187 + 61 NS 
Killip class 
I 99 95 NS 
II I8 15 NS 
111 ? ? NS 
APSAC = anisoylated plasminogen streptokinase activator complex: MI 
= myocardial infarction. NS = not significant; SD = standard deviation. 
Table 2. Clinical Course in Hospital 
In-hospital mortalit! 
(at ?I daysi 
Recurrence of pain 
Kilhp class (at 21 days1 
I 
II 
III 
AIVK 
VT VF 
Coronary angloplasty 
Coronary bypass 
surgery 
Heparin 
(n = 119) 
6 
7 
9x 
II 
3 
I! 
6 
7 
IO 
APSAC 
(n = II?) p Value 
7 NS 
IJ NS 
97 NS 
x NS 
0 NS 
?J NS 
I9 NS 
20 NS 
5 NS 
AIVR = accelerated idioventricular rhythm: NS = not significant: VF = 
ventricular fibrillation; VT = ventricular tachycardia. Other abbreviations as 
in Table 1. 
heparin and I I2 received APSAC. The average age, gender 
distribution, time of randomization, infarct site and func- 
tional status at admission were similar in both groups. 
Clinical course in the hospital (Table 2). Thirteen patients 
died during the hospital phase (six in the heparin group and 
seven in the APSAC group), including one who died from 
massive gastrointestinal bleeding on day I5 while receiving 
heparin therapy. The frequency of congestive heart failure 
and of ventricular arrhythmias tended to be lower in the 
APSAC group than in the heparin group. Recurrence of 
chest pain along with ECC and serum enzyme changes 
consistent with reinfarction were observed in twice as many 
patients in the APSAC group as in the heparin group. 
Side effects (Table 3). Bleeding complications requiring 
transfusion were observed in four APSAC-treated patients. 
A transient decrease in blood pressure after injection of the 
drug was observed in I heparin-treated patient and 12 
APSAC-treated patients (p < 0.01). Discontinuation of ni- 
trates and infusion of a plasma substitute were necessary to 
restore the arterial pressure to its pretreatment values in 
only three APSAC-treated patients. 
Coronary angiography (Table 4). Coronary angiography 
was obtained in 21 I patients (105 heparin-treated and 106 
APSAC-treated patients) 3.9 ? I .2 days after the initiation of 
Table 3. Side Effects Observed in Both Treatment Groups 
Heparin APSAC 
(n = 119) (n = II?) p Value 
Bleeding I 8 co.01 
Transfusion I 4 
Blood pressure decrease I 12 co.01 
Allergic rash 0 2 
Heparin-linked thrombocytopenia I 0 
.4PSAC = anisoylated plasminogen streptokinase activator complex. 
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Table 4. Distribution of Coronary Lesions, Collateral Circulation 
and Infarct-Related Artery in Both Treatment Groups 
Heparin 
(n = 105) 
APSAC 
(n = 106) p Value 
Infarct-related artery 
LAD 
LCX 
RCA 
Other 
Patent IRA 
No. of vessels involved 
Nonsignificant lesion 
One vessel disease 
Two vessel disease 
Three vessel disease 
Collateral circulation 
None 
Present 
Abundant 
39 37 NS 
IS 17 NS 
48 52 NS 
3 0 NS 
38 (36%) 82 (77%) 0.001 
5 12 NS 
55 54 NS 
26 29 NS 
19 I1 NS 
84 97 
16 6 
5 3 
<O.Ol 
<O.Ol 
IRA = infarct-related artery; LAD = left anterior descending coronary 
artery; LCx = left circumflex coronary artery; NS = not significant: RCA = 
right coronary artery. Other abbreviations as in Table 1. 
therapy in the APSAC group and 4.1 +- 1.3 days in the 
heparin group (p = NS). The infarct-related artery was 
patent in 38 heparin-treated patients (36%) and in 82 
APSAC-treated patients (77%) (p < 0.001). One hundred 
eighty patients underwent coronary arteriography between 
day 2 and day 6 after the onset of therapy. The day to day 
patency rate (Fig. 3) ranged from 75% on day 2 to 86% on 
day 5 in the APSAC group and from 26% on day 2 to 42% on 
day 3 in the heparin group. The proportion of one, two and 
three vessel disease was similar in both groups. Collateral 
circulation to the infarct-related artery was more frequently 
present in the heparin group. 
Revascularization procedures. Immediate angioplasty of 
the infarct-related artery was attempted in 30 patients and 
was successful in 29 (7 in the heparin group and 22 in the 
APSAC group). Coronary artery bypass surgery was per- 
formed during the in-hospital course in 10 heparin-treated 
Figure 3. Day to day patency rate of the infarct-related artery in both 
treatment groups. 
PATENCY RATE IN % 
DAY 2 DAY 3 DAY 4 DAY 5 DAY 6 
[I HEPARIN ??APSAC 
Table 5. Average Left Ventricular Ejection Fraction and 
Dyssynergic Score Estimated From Contrast Left Ventricular 
Angiography on Day 4 in 209 Patients 
LVEF 
Heparin APSAC p Value 
All 
Anterior MI 
Inferior MI 
Dyssynergic score 
0.47 2 0.12 0.53 + 0.13 0.002 
0.40 t 0.11 0.47 k 0.13 0.04 
0.51 ? 0.11 0.56 + 0.10 0.02 
All 13.3 5 9 9.8 ? 6 0.001 
Anterior Ml 18.8 + 8 13.3 2 7 0.002 
Inferior Ml 9.3 k 4 7.7 2 4 0.04 
LVEF = left ventricular ejection fraction; MI = myocardial dysfunction. 
Other abbreviations as in Table I. 
and 5 APSAC-treated patients. Except for two APSAC- 
treated patients with three vessel disease and recurring 
symptoms who underwent emergency bypass surgery, all 
patients were referred to surgery after completion of the 
study. The indication for surgery in each case was three 
vessel disease with preserved left ventricular function and 
demonstrable residual ischemia. 
Left ventricular function (Table 5). Left ventricular angi- 
ography was suitable for quantitative analysis in 209 pa- 
tients. A significant difference in the left ventricular ejection 
fraction and in the dyssynergic score appeared between the 
two treatment groups. The difference was more important in 
the anterior infarction subgroup, but was also significant in 
the inferior infarction subgroup (Table 5). 
Radionuclide angiography and single photon emission 
computed tomography were performed on day 19 + 2 in the 
APSAC group and day 19 ? 3 in the heparin group. Radio- 
nuclide angiography was available and suitable for analysis 
in 179 patients. A significant difference appeared between 
the two treatment groups, but only in the anterior infarction 
subgroup (Table 6). The difference in regional wall motion 
was significant in the septal and anteroapical zones and to a 
lesser extent in the lateral zone of the left ventricle in the 
entire APSAC group (Fig. 4). In the anterior infarction 
subgroup, the difference was significant in the anteroapical 
zone (Fig. 5). In the inferior infarction subgroup, a signifi- 
cant difference appeared in the septal zone (Fig. 6). 
Infarct size (Table 6). Interobserver reproducibility was 
0.95, and intraobserver reproducibility was 0.98 and 0.97 for 
the two observers. There was a highly significant difference 
between the two treatment groups. On average, infarct size 
was 31% lower in the APSAC group than in the heparin 
group. In the anterior infarction subgroup, the difference 
between the two treatment groups reached a significant 33%, 
whereas it was only 16% in the inferior infarction subgroup, 
thus failing to reach statistical significance. A significant 
inverse relation between infarct size and left ventricular 
ejection fraction was found in the entire study group, as well 
as in each treatment group (Fig. 7). 
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Figure 4. Left ventricular ejection fraction (LVEF) and sector Figure 6. Left ventricular ejection fraction (LVEF) and sector 
ejection fraction (regional wall motion) in the entire study group. ejection fraction (regional wall motion) in the inferior infarction 
Left ventricular ejection fraction is higher in the APSAC-treated subgroup. There was no significant difference in the values for global 
group than in the heparin-treated group, with significant improve- left ventricular ejection fraction. Regional wall motion is slightly 
ment in regional wall motion in the septal and apical zones. The inset better in the septal zone in the APSAC-treated group than in the 
represents the normal range for sector ejection fractions. heparin-treated group. 
Biologic data. There was no significant differences in 
blood cell count or hemoglobin levels between the two 
groups at 24 h. Creatine kinase levels were significantly 
higher at 6 h (1,329 t 1,127 versus 680 ? 567 NJ/liter, p < 
0.001) and significantly lower at 24 h (1,075 ? 815 versus 
1,331 _t 930 IUiliter, p < 0.05) in the APSAC group than in 
the heparin group. Fibrinogen levels did not change signifi- 
cantly in the heparin group; in the APSAC group it averaged 
0.46 + 0.5 g/liter at 6 h and 1.36 ? 0.87 g/liter at 24 h. 
Discussion 
Our study demonstrates that the intravenous administra- 
tion of APSAC in acute myocardial infarction leads to a 
significant preservation of left ventricular function. This 
improvement is the result of a significant limitation in infarct 
Figure 5. Left ventricular ejection fraction (LVEF) and sector 
ejection fraction (regional wall motion) in the anterior infarction 
subgroup. Left ventricular ejection fraction is higher in the APSAC- 
treated group than in the heparin-treated group, with significant 
improvement in regional wall motion in the apical zone. 
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size obtained through a high patency rate of the infarct- 
related artery. 
Preservation of left ventricular function by APSAC. To 
our knowledge, no similar studies aimed at estimating either 
left ventricular function or infarct size have been performed 
with APSAC. In this study, left ventricular ejection fraction 
determined from contrast angiography was significantly 
higher in the APSAC group than in the heparin group for all 
patients studied. as well as for the subgroups of patients with 
anterior or inferior infarction. Similarly, regional wall mo- 
tion was significantly less impaired in the APSAC-treated 
than in the heparin in both the anterior and inferior infarction 
subgroups. These findings are similar to those of Serruys et 
al. (221, who compared intracoronary streptokinase and 
conventional therapy, those of White et al. (23), who com- 
pared intravenous streptokinase and placebo and those of 
Guerci et al. (24), who compared intravenous rt-PA and 
placebo. The difference in left ventricular function observed 
between the two treatment groups at early analysis must be 
primarily regarded as the result of the beneficial effect of 
Table 6. Average Left Ventricular Ejection Fraction and Infarct 
Size Measured on Day I9 in 179 Patients 
RNA EF 
All 
Anterior MI 
Inferior Ml 
Infarct size 
All 
Anterior MI 
Inferior Ml 
Heparin APSAC p Value 
0.39 ir 0.12 0.43 IT 0.12 0.04 
0.32 2 0.13 0.38 -+ 0.13 0.045 
0.45 + 0.09 0.47 t 0.08 NS 
19 i I4 13 -t II 0.01 
?7-+ I6 I8 +- I5 0.01 
I? i 8 10 2 7 NS 
Infarct size is expressed as a percent of total myocardial mass. MI = 
myocardial infarction: RNA EF = left ventricular ejection fraction measured 
from radionuclide angiography: other abbreviations as in Tables 1 and 5. 
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Figure 7. Close inverse linear relation linking tomogra- 
phic (SPECT) infarct size and radionuclide left ven- 
tricular (LV) ejection fraction at the third week after 
symptom onset. The slope of the relation is steeper in 
the APSAC-treated group than in the heparin-treated 
group because left ventricular ejection fraction is 
higher and infarct size lower in the former group. 
SpEcT INFARCT SIZE SECT INFARCT SIZE 
early reperfusion induced by APSAC. The drug regimen was 
the same in both treatment groups except for the first 4 h 
after the start of treatment, during which patients received 
either APSAC or heparin (the latter drug is not known to 
have thrombolytic properties or myocardial salvaging 
effects). Contrast left ventricular angiography was per- 
formed within the same average time interval after the onset 
of symptoms in both groups. More successful coronary 
angioplasty procedures were performed in the APSAC group 
than in the heparin group, but were always performed after 
contrast angiography. Therefore, an additional therapeutic 
effect of coronary angioplasty on the jeopardized myocar- 
dium resulting in an improved left ventricular systolic func- 
tion in the APSAC group can be ruled out at early analysis, 
but not at the late (week 3) analysis. 
The beneficial effect on left ventricular ejection fraction 
was confirmed by analysis within the 3rd week after symp- 
tom onset, but was less apparent than at 4 days, particularly 
in the inferior infarction subgroup in which the difference 
was no longer significant. This fact was consistent with a 
nonsignificant reduction of infarct size in this patient sub- 
group. Most of the trials (22-27) aimed at estimating the 
beneficial effect of thrombolytic therapy on left ventricular 
function have shown left ventricular ejection fraction to be 
significantly improved in anterior infarction. In inferior 
infarction, however, the differences were often less striking, 
and on some occasions were nonsignificant (25-27). Several 
reasons may account for this lack of significant improvement 
in left ventricular function in inferior infarction: 1) the 
sample size may have been too small to demonstrate the 
statistical significance of the observed difference; 2) the left 
ventricular mass at risk is smaller in inferior than in anterior 
infarction, and thus a smaller amount of myocardium may be 
salvaged in cases of early reperfusion; and 3) collateral flow 
to the infarct-related artery is often more abundant in 
inferior infarction, thus limiting the detrimental effect of 
coronary occlusion on the jeopardized myocardium (27). 
Furthermore, technical reasons may partly explain the 
discrepancies observed in our trial between early and late 
evaluation of left ventricular systolic function. Early estima- 
tion was done from contrast angiography, performed under 
nitroglycerin infusion at a period during which the adrener- 
gic drive was still high. In this early analysis, both nitrate 
infusion and increased adrenergic drive could have enhanced 
the wall motion of the noninfarcted area. At late analysis, the 
adrenergic drive had returned to normal levels. Further- 
more, left ventricular ejection fraction was estimated with- 
out nitrates, which may explain why the differences in terms 
of left ventricular systolic function were partially offset in 
the whole group and no longer significant in the inferior 
infarction subgroup at late analysis. Moreover, the patient 
samples tested at early and late analysis were not exactly the 
same because 209 patients underwent contrast angiography 
and only 179 had radionuclide angiography. The missing data 
were due to patient death, patient refusal, unavailability of a 
gamma camera or unsuitable acquisitions and were equally 
distributed in both treatment groups. 
Limitation of infarct size. Single photon emission com- 
puted tomography cannot differentiate between the scar of a 
previous myocardial infarction and the perfusion defect of a 
recent myocardial infarction. Therefore, to avoid any possi- 
ble bias in interpreting the observed difference in infarct size 
between the two treatment groups, we chose not to include 
in the study those patients with recurrent infarction. The 
difference in infarct size effectively observed must, there- 
fore, be regarded as fully representing the salvaging effect 
produced by early reperfusion. 
Infarct size was estimated by the original method of 
Maublant et al. (20) developed and validated in animal 
models. This method has been shown to produce accurate 
measurements of infarct size in dogs. So far, it has not been 
applied in clinical studies to estimate the ability of throm- 
bolytic therapy to reduce infarct size. The acquisition of data 
at all three university centers was carried out with great 
caution. The same labeling techniques, computer program 
and cameras were used to ensure the most uniform acquisi- 
tion possible. Furthermore, all acquisitions were processed 
by the same two experienced senior physicians, who had 
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described and validated the method in animals. Inter- and 
intraobserver variability was very low. Ritchie et al. (28) also 
used single photon emission computed tomography to quan- 
tify infarct size in patients receiving either intracoronary 
streptokinase or conventional heparin therapy within 12 h 
after the onset of symptoms of acute myocardial infarction. 
They found no significant difference between their two 
patient groups, probably because of the excessive delay 
between the onset of symptoms and the initiation of therapy 
in their study. Interestingly, infarct size averaged 19% in 
both of their groups. a value similar to that of the heparin 
group in our study. 
A significant reduction qf infarct size, averaging 31% in 
the entire study group, 33% in the anterior infarction sub- 
group but only 16% in the inferior infarction subgroup, was 
observed in our study. The salvaging effect was of the same 
magnitude as that determined by Van Der Laarse et al. (29) 
with the serum enzyme release method. Infarct size in our 
study was closely and inversely correlated to left ventricular 
ejection fraction estimated from radionuclide studies, thus 
supporting the validity of our method of determining infarct 
size. This also confirmed that the preservation of left ven- 
tricular systolic function was mediated by the limitation of 
infarct size. Such a relation between infarct size and systolic 
performance was previously shown (29) in the determination 
of infarct size based on serum enzyme release. 
However. our method contuins some limitations. The 
limits of the perfusion defect of the infarct area can only be 
estimated by the operator. Very large defects cannot be 
accurately outlined without a good knowledge of the shape 
of the normal left ventricular myocardium. Therefore, some 
experience in drawing the missing part of the wall is manda- 
tory. Interestingly, in our study, the differences between the 
data of the two observers were not greater for large than for 
small infarcts. 
Patency rate of the infarct-related artery: reocclusion rate. 
The average patency rate estimated on day 4 was particu- 
larly high, reaching 77%, a value that favorably compares 
with the patency rate obtained with other thrombolytic 
agents (5). For obvious reasons, neither the reperfusion rate 
nor the reocclusion rate could be estimated from this study. 
Anderson et al. (17) observed a 60% reperfusion rate when 
APSAC was administered within 4 h after the onset of 
symptoms, a value also given by Monk et al. (6) from 
pooled data. The reocclusion rate has been estimated to be 
very low with APSAC, and as low as 10% without additional 
procedures (6,10.17). In our study, clinical evidence of 
reinfarction was observed in 13% of APSAC-treated pa- 
tients. This rate may indirectly indicate the reocclusion rate 
in the APSAC group. Another approach is given by the day 
to day analysis of patency rate. In both groups, the patency 
rate was relatively constant during the first 5 days of 
evolution. This relative stability may indicate that the reoc- 
elusion rate was low or offset by an equivalent spontaneous 
reperfusion rate, which is nevertheless not apparent from the 
measurements of day to day patency rate in the heparin 
group. 
In-hospital mortality rate. Despite the beneficial effect of 
APSAC on infarct size and left ventricular systolic function, 
no significant reduction in mortality rate was observed in this 
study. Mortality rate was not the primary end point of this 
study, which was designed to involve at most 250 patients, a 
number too small to allow demonstration of the statistical 
significance of a possible difference in mortality rate. If we 
accept the idea that left ventricular ejection fraction is the 
main determinant of late survival, as suggested in previous 
trials (30.31). our study would lead us to expect a reduction 
in the 1 year mortality rate. A 47% reduction in mortality 
rate was recently demonstrated in a larger trial (32) in which 
similar doses of APSAC were administered up to 6 h after 
the onset of symptoms. 
Bleeding complications and side effects. The bleeding 
complication rate produced by APSAC is well known from 
other trials (6.17.32) and favorably compares with that from 
thrombolytic agents with (33) or without (23,25,34) fibrin 
specificity. In this trial, a bleeding complication was ob- 
served in 6.5%~ of the APSAC-treated patients, and only half 
of these patients required a blood transfusion. The only 
lethal bleeding complication in this trial was not directly 
attributable to APSAC. The magnitude and frequency of the 
decrease in blood pressure in our study were far lower than 
those observed with intravenous streptokinase (5,6,17). 
Clinical implications. Our study shows that APSAC can 
be used safely and efficiently in community hospitals without 
catheterization facilities-the centers to which the vast 
majority of patients with acute myocardial infarction are 
initially referred. Anisoylated plasminogen-streptokinase ac- 
tivator complex (APSAC) is easy to administer and induces 
a high reperfusion rate, significant limitation of infarct size 
and significant preservation of left ventricular systolic func- 
tion that may eventually result in a reduced mortality rate, as 
observed in the AIMS trial (32). 
The questions of timing and the need for coronary angi- 
ography and additional revascularization procedures remain 
unanswered. One large scale trial (35) failed to demonstrate 
any significant additional beneficial effect on left ventricular 
systolic function or on the reocclusion rate after emergency 
angioplasty as compared with elective angioplasty. In so far 
as the conclusions from that trial (35) conducted with rt-PA 
can be applied to trials conducted with other thrombolytic 
agents, there are no convincing data justifying emergency 
angioplasty and, therefore, emergency coronary angiogra- 
phy. 
We are indebted to Marie-ThCr&e Liegeon, Marie-ThCr&se Humbert, Sylvie 
Cuisance and RenCe Bassand for the preparation of the manuscript. and to 
Nancy Rxhardson for reviewing the text. 
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Appendix IO. 
Physicians and centers participating in the multicenter trial 
Georges Amat, MD, Centre Hospitalier. 03200 Vichy, France. 
Frangoise Apfel, MD, Centre Hospitalier, Service de Cardologie, 39100 
Dole. France. 
II. 
Jean Daniel Berthou, MD, Centre Hospitalier, Service de Cardiologie. 
39000 Lons le Saunier, France. 
Jean Louis Chapoutot, MD, Centre Hospitalier, Service de Cardiologie, 
70000 Vesoul, France. 
12. 
Pierre Daoudal, MD, Centre Hospitalier, Service de Reanimation M&di- 
tale, 70000 Vesoul, France. 13. 
Robert Dimitriou, MD, Centre Hospitalier, 38500 Voiron, France. 
AndrP Hirsch, MD, Centre Hospitalier, 84000 Avignon, France. 
Yves Laurent, MD, Centre Hospitalier, 73300 St. Jean de Maurienne. 
France. 14. 
Michel Lewintre, MD, Centre Hospitalier, 73200 Albertville, France. 
Jean-Pierre Louis, MD, Centre Hospitalier, Service de Cardiologie. 25200 
Montbeliard, France. 
Louis Louvart de Pontlevoye, MD, Centre Hospitalier, Service de Cardio- 
logic, 25300 Pontarlier, France. 
IS. 
Michel Pailloncy, MD, Centre Hospitalier, 63500 Issoire, France. 
Marie Claire Palcoux, MD, Centre Hospitalier, 63200 Riom, France. 
Freddi Rauscher, MD, Centre Hospitalier, Service de Cardiologie, 90000 
Belfort, France. 16. 
GCrard Rey, MD, Centre Hospitalier, 73100 Aix les Bains, France. 
Michel Ricoux, MD, Centre Hospitalier, 03100 Montlucon, France. 
Bruno Rossignol, MD, Clinique Mutualiste, 38000 Grenoble, France. 
CCrard Sihoni, MD, Centre Hospitalier. 03000 Moulins, France. 
Dominique Simonin, MD, Centre Hospitalier. 74100 Annemasse, France. 
Michel Viallet, MD, Centre Hospitalier, 43000 Le Puy, France. 
Andre Veyrat, MD, Centre Hospitalier, 73000 Chambery, France. 
Anne Zehrowski, MD, Centre Hospitalier, 05100 Briancon. France. 
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